Anixa Biosciences, Inc. (ANIX) Stock

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc. is led by CEO Amit Kumar, employs 5 people, headquartered in US, publicly traded since 1983.

Anixa Biosciences, Inc. (ANIX) stock trades at $2.99 with a market capitalization of $103.94M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.67, reflecting a net loss over the last twelve months, price-to-book of 6.97, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.32 and $5.46, and currently trades 45.2% below its 52-week high.

On profitability, Anixa Biosciences, Inc. generates a return on equity (ROE) of -70.44% (negative, reflecting a net loss), return on capital employed of -82.35%.

Anixa Biosciences, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Anixa Biosciences, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-11.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-12.0M.

Borrowings fell from $4.0M to $0, cash from operations was $-7.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -53.1% over five years, and was -73.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Anixa Biosciences, Inc. (ANIX) — frequently asked questions